Foscavir is a medicine containing the active ingredient(s) foscarnet. On this page you will find out more about Foscavir, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: foscarnet
Information for medicine and pack size:
Foscavir 6 g/250 mL injection solution, 250 mL bottle
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS). INDICATIONS AS AT 11 NOVEMBER 1994: For treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS); and treatment of aciclovir resistant herpes simplex virus (HSV) infections (defined by clinical trial or in-vitro resistance) in immunocompromised patients with human immunodeficiency virus (HIV) infection. NOTE: the indication for treatment of aciclovir resistant HSV infections in immunocompromised patients with HIV infections is based primarily on the results of one open label comparative study. This was of patients with HIV infections and herpetic lesions unresponsive to aciclovir administered intravenously for 10 days or more and in-vitro documented resistance to aciclovir. Eight patients were randomised to foscarnet (40mg/kg IV given eight hourly) and 6 were randomised to vidarabine 15mg/kg IV daily. The results showed a significant difference in favour of the foscarnet treatment group for clinical and virological endpoints, especially in time to complete healing of lesions and time to complete loss of pain. In 177 other patients treated with foscarnet in non-comparative studies, results were sufficiently similar to support the efficacy of foscarnet in this indication.
Table of characteristics
|Visual appearance||A clear colourless solution.|
|Dosage Form||Injection, solution|
|Route of administration||Intravenous|
250mL X 1: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||Do not Refrigerate|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.